NASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis $0.28 -0.01 (-4.86%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$0.29 +0.01 (+3.93%) As of 04/4/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About FibroGen Stock (NASDAQ:FGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FibroGen alerts:Sign Up Key Stats Today's Range$0.27▼$0.3250-Day Range$0.28▼$0.7752-Week Range$0.18▼$1.74Volume1.69 million shsAverage Volume2.28 million shsMarket Capitalization$28.26 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company OverviewFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Read More… Remove Ads FibroGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreFGEN MarketRank™: FibroGen scored higher than 86% of companies evaluated by MarketBeat, and ranked 106th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingFibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFibroGen has only been the subject of 2 research reports in the past 90 days.Read more about FibroGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about FibroGen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.04% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently decreased by 6.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.84 Percentage of Shares Shorted5.04% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently decreased by 6.04%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.31 News SentimentFibroGen has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for FibroGen this week, compared to 1 article on an average week.Search Interest6 people have searched for FGEN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $138,250.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.98% of the stock of FibroGen is held by insiders.Percentage Held by Institutions72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about FibroGen's insider trading history. Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Stock News HeadlinesInsider Buying: FibroGen, Inc. (NASDAQ:FGEN) CEO Purchases 145,000 Shares of StockMarch 26, 2025 | insidertrades.comFibroGen, Inc. (NASDAQ:FGEN) Director Buys $87,500.00 in StockMarch 25, 2025 | insidertrades.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 5, 2025 | Premier Gold Co (Ad)Q1 Earnings Forecast for FibroGen Issued By William BlairApril 5 at 2:53 AM | americanbankingnews.comFibroGen's (FGEN) Market Perform Rating Reiterated at William BlairApril 3 at 1:49 AM | americanbankingnews.comWilliam Blair Keeps Their Hold Rating on FibroGen (FGEN)April 2 at 4:47 PM | markets.businessinsider.comFibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 4:05 PM | globenewswire.comFibroGen extends merger option deadline with FortisMarch 30, 2025 | investing.comSee More Headlines FGEN Stock Analysis - Frequently Asked Questions How have FGEN shares performed this year? FibroGen's stock was trading at $0.5295 at the start of the year. Since then, FGEN shares have decreased by 47.1% and is now trading at $0.28. View the best growth stocks for 2025 here. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) issued its quarterly earnings results on Monday, March, 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $3.14 million for the quarter, compared to analysts' expectations of $24.91 million. When did FibroGen IPO? FibroGen (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings3/17/2025Today4/05/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FGEN CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees570Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+3,471.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-284,230,000.00 Net Margins-67.66% Pretax Margin-69.56% Return on EquityN/A Return on Assets-36.17% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.16 Sales & Book Value Annual Sales$29.62 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value($1.87) per share Price / Book-0.15Miscellaneous Outstanding Shares100,917,000Free Float98,775,000Market Cap$28.26 million OptionableOptionable Beta0.82 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:FGEN) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.